减毒株CP-65 K作为牛痘疫苗候选株的免疫生物学特性评价
本研究评价减毒株CP-65 K开发牛痘疫苗的适用性与免疫生物学特性。CP-65 K对实验室动物和目标动物均无反应原性,免疫原性高于VACV株RIBSP-B、RIBSP-V及CMLV株KM-40。连续传15代后感染滴度保持稳定,接种兔第21天产生特异性抗体;接种牛第14天检出抗原特异性抗体且加强后升高,但未观察到T细胞应答的统计学显著激活;攻毒后接种动物无临床牛痘症状而对照动物发病。
要点
- CP-65 K无反应原性且免疫原性高于VACV株RIBSP-B、RIBSP-V和CMLV株KM-40
- 连续传15代后感染滴度保持6.50±0.14至6.67±0.08 log₁₀ TCID₅₀/mL
- 攻毒后接种动物无临床牛痘症状,对照动物出现发热和皮肤病变
核心结论
- 减毒株CP-65 K无反应原性且免疫原性优于VACV株RIBSP-B、RIBSP-V及CMLV株KM-40,支持其作为牛痘活疫苗候选株。
研究设计与样本
- 评估减毒株CP-65 K的免疫生物学特性,在实验室动物和目标动物中测试反应原性与免疫原性。
- 在羔羊肾细胞培养中连续传15代评估表型稳定性,并向实验室动物给予3162至316,200 TCID₅₀剂量。
- 以10,000 TCID₅₀皮下免疫,采用VNT和ELISA检测体液免疫,并在接种后第30天以Cowpox-CAM株攻毒。
主要发现
- 连续传15代后CP-65 K感染滴度维持在6.50±0.14至6.67±0.08 log₁₀ TCID₅₀/mL。
- 接种兔在免疫后第21天产生特异性抗体。
- 3162至316,200 TCID₅₀剂量未引起临床显著不良反应或死亡。
- 10,000 TCID₅₀皮下免疫诱导强体液免疫,VNT中和抗体滴度为1:16至1:64,ELISA光密度值为1.031-1.328。
- 接种牛自初次接种后第14天检出抗CPXV抗原特异性抗体,加强免疫后升高;攻毒后接种动物无临床牛痘症状,对照动物出现高热、特征性皮肤病变、局部坏死和全身感染证据;未观察到T细胞应答的统计学显著激活。
关键数值与推荐
- CP-65 K连续传15代后感染滴度范围为6.50±0.14至6.67±0.08 log₁₀ TCID₅₀/mL。
- 实验室动物给药剂量范围为3162至316,200 TCID₅₀。
- 皮下免疫剂量为10,000 TCID₅₀,VNT中和抗体滴度为1:16至1:64,ELISA光密度值为1.031-1.328。
- 接种牛初次接种后第14天检出抗原特异性抗体,攻毒于接种后第30天进行。
临床怎么用
- CP-65 K可作为牛痘活疫苗候选株进一步开发,其无反应原性且免疫原性优于所比较的VACV和CMLV株。
- 体液免疫应答可通过VNT和ELISA评估,接种后抗体出现时间与加强免疫提升效果可供免疫程序参考。
局限性
- 体外抗原特异性淋巴细胞增殖未伴随CD4+或CD8+ T细胞亚群增殖的统计学显著变化,增殖群体的细胞来源需进一步表型鉴定。
- 未观察到T细胞应答(包括CD4+/CD8+淋巴细胞比例变化及TNF-α、IFN-γ、IL-4表达)的统计学显著激活。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study evaluated the suitability and immunobiological characteristics of the attenuated strain CP-65 K for the development of a cowpox vaccine. The attenuated strain CP-65 K was non-reactogenic in both laboratory and target animals and demonstrated higher immunogenicity than vaccinia virus (VACV) strains RIBSP-B and RIBSP-V, as well as the camelpox virus (CMLV) strain KM-40, supporting its potential as a live vaccine candidate. After 15 serial passages in lamb kidney cell culture, CP-65 K retained its infectious titer (6.50 ± 0.14 to 6.67 ± 0.08 log₁₀ TCID₅₀/mL) and induced specific antibodies in vaccinated rabbits by day 21 post-immunization, confirming phenotypic stability. Administration of vaccine doses ranging from 3162 to 316,200 TCID₅₀ to laboratory animals caused no clinically significant adverse effects or mortality. Subcutaneous immunization with 10,000 TCID₅₀ induced a strong humoral immune response, with neutralizing antibody titers ranging from 1:16 to 1:64 in the virus neutralization test (VNT) and enzyme-linked immunosorbent assay (ELISA) optical density values of 1.031-1.328. In vaccinated cattle, antigen-specific antibodies against cowpox virus (CPXV) were detected from day 14 after primary vaccination and increased following booster immunization. However, no statistically significant activation of T-cell responses, including changes in CD4+/CD8+ lymphocyte populations or expression of TNF-α, IFN-γ, and IL-4 after in vitro CPXV stimulation, was observed. Challenge infection with the epizootic strain Cowpox-CAM on day 30 post-vaccination did not induce clinical signs of cowpox in vaccinated animals, whereas control animals developed hyperthermia, characteristic skin lesions, local necrosis, and evidence of systemic infection. Histological analysis confirmed pronounced local dermal lesions in non-vaccinated cattle. Antigen-specific lymphocyte proliferation observed in vitro was not accompanied by statistically significant changes in proliferating CD4+ or CD8+ T-cell subsets, and the cellular origin of the proliferating population requires further phenotypic characterization.
引用
- Muzarap D, Dzhaldybayeva A, Mambetaliyev M, et al. Evaluation of the immunobiological properties of the attenuated strain CP-65 K for the development of a cowpox vaccine. Vaccine. 2026. PMID: 42858679. doi:10.1016/j.vaccine.2026.129239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。